During a live event, Matthew Lunning, DO, and participants discussed the process of determining if patients with DLBCL should receive second-line CAR T-cell therapy.
Expanding Second-Line Therapy in B-cell Lymphoma with CAR T-Cell Therapy
During a live event, Matthew Lunning, DO, and participants discussed how identifying primary refractory and early relapsed DLBCL matters for using second-line CAR T-cell therapy.
During a live event, Priyanka Pophali, MD, MBBS, discussed CAR T-cell therapy referrals, timing, and challenges in relapsed or high-risk lymphoma.
During a live event, Priyanka Pophali, MD, MBBS, discussed CAR T-cell therapy caregiver challenges and referral considerations after DLBCL relapse.
During a live event, Nathan M. Denlinger, DO, MS, discussed the PILOT and ALYCANTE trials of CAR T-cell therapy in transplant-ineligible B-cell lymphoma.
During a live event, Nathan M. Denlinger, DO, MS, discussed the TRANSFORM trial of lisocabtagene maraleucel in B-cell lymphoma and its crossover design.
During a Case-Based Roundtable® event, Natalie Galanina, MD, reviewed how outcomes have changed in patients with primary refractory or early relapsed DBLCL since the introduction of CAR T-cell therapy.
During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first article of a 2-part series.
During a Case-Based Roundtable® event, Sairah Ahmed, MD, discussed the data behind the use of lisocabtagene maraleucel for patients with diffuse large B-cell lymphoma in the second article of a 2-part series.
During a Case-Based Roundtable® event, Sairah Ahmed, MD, discussed how the burgeoning use of chimeric antigen receptor T-cell therapy presents a paradigm shift in treatment for patients with diffuse large B-cell lymphoma in the first article of a 2-part series.
Matthew Lunning, DO, FACP, discusses the use of CAR T-cell therapy lisocabtagene maraleucel in the second-line setting for patients with B-cell lymphoma.